Guggenheim reiterates Alumis stock rating on psoriasis trial data

Envudeucitinib delivered PASI-90 rates of 62.1%-68.0% and PASI-100 rates of 39.5%-41.0% at Week 24 in ~1,771-patient Phase III ONWARD trials, prompting Guggenheim to reiterate a Buy with a $32 PT; Baird and Stifel issued $35 and $44 PTs while H.C. Wainwright cut its PT to $25. Alumis shares trade at $24.16 (market cap $3.15B), have surged ~340% over the past year, and the company expects an NDA submission in H2 2026 with Phase IIb lupus topline results due in Q3 2026. InvestingPro flags the stock as Most Overvalued despite strong efficacy and a clean safety signal, suggesting upside is supported by data but tempered by valuation and competitive pressures.

Analysis

A successful late‑stage readout for an oral TYK2 candidate shifts the competitive map from biologic-dominant psoriasis treatment economics toward an oral-first paradigm; the immediate beneficiaries are acquirers and partners (scale players who can commercialize broadly) and contract manufacturers with oral small-molecule capacity. Payers will reassess unit cost vs. adherence and monitoring burdens — if lab monitoring can be minimized, formularies will favor the oral option, compressing price premiums for injectables and forcing incumbent biologics makers to accelerate value-based contracting within 6–18 months.

Second‑order winners include CDMOs with high-volume oral solid-dose capability and specialty pharmacies that manage chronic oral regimens; losers are margin-exposed injectable supply chains (cold‑chain dependent sites) and companies whose psoriasis portfolios lack an oral offering, creating an M&A playbook where small oral candidates become levered acquisition targets. However, the path to durable commercial success is not binary: real-world safety signals, payer-mandated monitoring, or a more conservative label can erase >50% of modeled NPV for an oral launch within a 12–24 month window.

Near‑term catalysts that will move the stock beyond headline euphoria are regulatory feedback, payer coverage decisions from top PBMs, and any third‑party health‑economics data showing durable adherence; negative catalysts include postapproval safety flags or a pricing environment that forces >30% discounting versus modeled assumptions. The volatility profile suggests event-driven timeframes (days–weeks) around advisory/regulatory milestones and a multi‑quarter drift as payers and physicians update prescribing habits.

Contrarian risk: consensus appears to price in near‑term seamless uptake and zero lab monitoring — that’s a fragile assumption. We prefer a relative‑value approach that harvests the valuation gap between a small, binary‑risk developer and large incumbents while protecting against both headline and systemic pharma drawdowns.

Key Decisions for Investors

• Long ALMS equity (or calls) — horizon 6–12 months. Size 1–2% of portfolio. Target +30–60% upside vs stop at -20% absolute; hedge with a 3–6 month put or a short position in a small-cap oral competitor to neutralize class risk.
• Pair trade: long ALMS / short PTGX — horizon 3–9 months. Size net market exposure 0.5–1% of portfolio. Rationale: capture asymmetric upside from clearer data readout and partner optionality while shorting a smaller rival whose market share assumptions look optimistic; close when relative spread narrows >40% or on negative class safety signal.
• Protective hedge on incumbents: buy JNJ 3–6 month put spreads (small notional) — horizon 3 months. Costed hedge to capture >1:3 payoff if payer re-prices injectable biologics; use 5–10% OTM strikes to limit premium and be activated on sustained share erosion headlines.
• Avoid outright long exposure to injectable makers without optionality clauses — instead allocate to CDMOs and specialty pharmacy operators with 9–18 month upside as indirect beneficiaries; use 6–12 month covered-call overlays to monetize near-term volatility.